Literature DB >> 24697337

Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia.

Lieke C J van den Berk1, Arian van der Veer, Marieke E Willemse, Myrte J G A Theeuwes, Mirjam W Luijendijk, Wing H Tong, Inge M van der Sluis, Rob Pieters, Monique L den Boer.   

Abstract

Malignant cells infiltrating the bone marrow (BM) interfere with normal cellular behaviour of supporting cells, thereby creating a malignant niche. We found that CXCR4-receptor expression was increased in paediatric precursor B-cell acute lymphoblastic leukaemia (BCP-ALL) cells compared with normal mononuclear haematopoietic cells (P < 0·0001). Furthermore, high CXCR4-expression correlated with an unfavourable outcome in BCP-ALL (5-year cumulative incidence of relapse ± standard error: 38·4% ± 6·9% in CXCR4-high versus 12% ± 4·6% in CXCR4-low expressing cases, P < 0·0001). Interestingly, BM levels of the CXCR4-ligand (CXCL12) were 2·7-fold lower (P = 0·005) in diagnostic BCP-ALL samples compared with non-leukaemic controls. Induction chemotherapy restored CXCL12 levels to normal. Blocking the CXCR4-receptor with Plerixafor showed that the lower CXCL12 serum levels at diagnosis could not be explained by consumption by the leukaemic cells, nor did we observe an altered CXCL12-production capacity of BM-mesenchymal stromal cells (BM-MSC) at this time-point. We rather observed that a very high density of leukaemic cells negatively affected CXCL12-production by the BM-MSC while stimulating the secretion levels of granulocyte colony-stimulating factor (G-CSF). These results suggest that highly proliferative leukaemic cells are able to down-regulate secretion of cytokines involved in homing (CXCL12), while simultaneously up-regulating those involved in haematopoietic mobilization (G-CSF). Therefore, interference with the CXCR4/CXCL12 axis may be an effective way to mobilize BCP-ALL cells.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  BM-MSC; CXCL12; CXCR4; Plerixafor; paediatric acute lymphoblastic leukaemia

Mesh:

Substances:

Year:  2014        PMID: 24697337     DOI: 10.1111/bjh.12883

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  34 in total

Review 1.  A hostel for the hostile: the bone marrow niche in hematologic neoplasms.

Authors:  Daniela S Krause; David T Scadden
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

Review 2.  The role of G protein-coupled receptors in lymphoid malignancies.

Authors:  Adrienne Nugent; Richard L Proia
Journal:  Cell Signal       Date:  2017-08-09       Impact factor: 4.315

3.  Acute lymphoblastic leukemia cells create a leukemic niche without affecting the CXCR4/CXCL12 axis.

Authors:  Bob de Rooij; Roel Polak; Lieke C J van den Berk; Femke Stalpers; Rob Pieters; Monique L den Boer
Journal:  Haematologica       Date:  2017-06-15       Impact factor: 9.941

4.  Gene-expression and in vitro function of mesenchymal stromal cells are affected in juvenile myelomonocytic leukemia.

Authors:  Friso G J Calkoen; Carly Vervat; Else Eising; Lisanne S Vijfhuizen; Peter-Bram A C 't Hoen; Marry M van den Heuvel-Eibrink; R Maarten Egeler; Maarten J D van Tol; Lynne M Ball
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

5.  Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.

Authors:  Geoffrey L Uy; Yen-Michael S Hsu; Amy P Schmidt; Wendy Stock; Theresa R Fletcher; Kathryn M Trinkaus; Peter Westervelt; John F DiPersio; Daniel C Link
Journal:  Leuk Res       Date:  2015-10-01       Impact factor: 3.156

Review 6.  The functional interplay between systemic cancer and the hematopoietic stem cell niche.

Authors:  Amber J Giles; Christopher D Chien; Caitlin M Reid; Terry J Fry; Deric M Park; Rosandra N Kaplan; Mark R Gilbert
Journal:  Pharmacol Ther       Date:  2016-09-02       Impact factor: 12.310

7.  The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.

Authors:  Dagmar Schinnerl; Klaus Fortschegger; Maximilian Kauer; João R M Marchante; Reinhard Kofler; Monique L Den Boer; Sabine Strehl
Journal:  Blood       Date:  2014-12-16       Impact factor: 22.113

Review 8.  Navigating the bone marrow niche: translational insights and cancer-driven dysfunction.

Authors:  Michaela R Reagan; Clifford J Rosen
Journal:  Nat Rev Rheumatol       Date:  2015-11-26       Impact factor: 20.543

9.  Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia.

Authors:  Shubhchintan Randhawa; Byung S Cho; Dipanjan Ghosh; Mariela Sivina; Stefan Koehrer; Markus Müschen; Amnon Peled; Richard E Davis; Marina Konopleva; Jan A Burger
Journal:  Br J Haematol       Date:  2016-04-12       Impact factor: 6.998

10.  CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion.

Authors:  Chun-Hui Jin; Yang Li; Jinxing Xia; Yuying Li; Mo Chen; Zheng Hu; Markus Y Mapara; Wei Li; Yong-Guang Yang
Journal:  Am J Hematol       Date:  2018-04-16       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.